November 14, 2022
2 min watch
Save
VIDEO: FDA accepts new drug application for Demodex blepharitis treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW YORK — In a Healio Video Perspective from OSN New York, Aziz Mottiwala, of Tarsus Pharmaceuticals, discusses the FDA acceptance of the new drug application for TP-03 for the treatment of Demodex blepharitis.
Mottiwala also discusses the company’s “Look at the Lids” campaign to help educate specialists on diagnosing Demodex blepharitis.
The PDUFA target action date for TP-03 is Aug. 25, 2023.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Mottiwala reports being the chief commercial officer of Tarsus Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.